Biomarkers for Therapeutic Monitoring of Ovarian Cancer


A method for assessing therapeutic outcome of a treatment for ovarian cancer comprising determining the amount of one or more proteins in a blood sample from a ovarian cancer patient who is at remission after treatment, wherein the one or more proteins are selected from the group consisting of siCAM1, sTNFR-II, RANTES, sgpl30, MMP-2, CA15-3, MIG, sVCAM-1, TPO, sTNFR-I and MDC and combinations thereof, and wherein elevated serum amounts of the one or more proteins or reduced level of MDC relative to a control indicates that the subject has poor overall survival relative to subjects in remission for ovarian cancer having lower serum amounts of the one or more serum proteins or higher MDC.


GRU #2012-027

Patent Information:
For Information, Contact:
Carl Clark
Director Technology Transfer
Augusta University
Jin-Xiong She
Ashok Sharma
© 2022. All Rights Reserved. Powered by Inteum